Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric Solary

Showing results (191-200 of 273) with videos related to

Pageof 28
Sort By:
Blood|March 22, 2023
Structural variation cooperates with permissive chromatin to control enhancer hijacking-mediated oncogenic transcriptionGiovanni A Botten, Yuannyu Zhang, Kseniia Dudnyk, et al.
Blood|January 9, 2014
Germ-line JAK2 mutations in the kinase domain are responsible for hereditary thrombocytosis and are resistant to JAK2 and HSP90 inhibitorsCaroline Marty, Cécile Saint-Martin, Christian Pecquet, et al.
Nature Communications|May 19, 2017
ASXL2 is essential for haematopoiesis and acts as a haploinsufficient tumour suppressor in leukemiaJean-Baptiste Micol, Alessandro Pastore, Daichi Inoue, et al.
Communications Biology|November 23, 2024
Targeting heterochromatin eliminates chronic myelomonocytic leukemia malignant stem cells through reactivation of retroelements and immune pathwaysDonia Hidaoui, Audrey Porquet, Rabie Chelbi, et al.
Blood|March 29, 2003
Quinine as a multidrug resistance inhibitor: a phase 3 multicentric randomized study in adult de novo acute myelogenous leukemiaEric Solary, Bernard Drenou, Lydia Campos, et al.
Leukemia|July 21, 2018
Heterogeneous expression of cytokines accounts for clinical diversity and refines prognostication in CMMLSandrine Niyongere, Nolwenn Lucas, Jun-Min Zhou, et al.
Haematologica|October 3, 2009
TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemiaOlivier Kosmider, Véronique Gelsi-Boyer, Marion Ciudad, et al.
Stem Cells (Dayton, Ohio)|April 12, 2014
TET2 deficiency inhibits mesoderm and hematopoietic differentiation in human embryonic stem cellsThierry Langlois, Barbara da Costa Reis Monte-Mor, Gaëlle Lenglet, et al.
Plos One|September 26, 2013
Heterozygous and homozygous JAK2(V617F) states modeled by induced pluripotent stem cells from myeloproliferative neoplasm patientsJoseph Saliba, Sofiane Hamidi, Gaëlle Lenglet, et al.
Leukemia|September 12, 2024
Eltrombopag in chronic myelomonocytic leukemia with severe thrombocytopenia. A Groupe Francophone des Myélodysplasies (GFM) studyFlorence Rabian, Sylvie Chevret, Bérengère Gruson, et al.
Pageof 28

Showing results (191-200 of 273) with videos related to

Sort By:
Pageof 28
Blood|March 22, 2023
Structural variation cooperates with permissive chromatin to control enhancer hijacking-mediated oncogenic transcriptionGiovanni A Botten, Yuannyu Zhang, Kseniia Dudnyk, et al.
Blood|January 9, 2014
Germ-line JAK2 mutations in the kinase domain are responsible for hereditary thrombocytosis and are resistant to JAK2 and HSP90 inhibitorsCaroline Marty, Cécile Saint-Martin, Christian Pecquet, et al.
Nature Communications|May 19, 2017
ASXL2 is essential for haematopoiesis and acts as a haploinsufficient tumour suppressor in leukemiaJean-Baptiste Micol, Alessandro Pastore, Daichi Inoue, et al.
Communications Biology|November 23, 2024
Targeting heterochromatin eliminates chronic myelomonocytic leukemia malignant stem cells through reactivation of retroelements and immune pathwaysDonia Hidaoui, Audrey Porquet, Rabie Chelbi, et al.
Blood|March 29, 2003
Quinine as a multidrug resistance inhibitor: a phase 3 multicentric randomized study in adult de novo acute myelogenous leukemiaEric Solary, Bernard Drenou, Lydia Campos, et al.
Leukemia|July 21, 2018
Heterogeneous expression of cytokines accounts for clinical diversity and refines prognostication in CMMLSandrine Niyongere, Nolwenn Lucas, Jun-Min Zhou, et al.
Haematologica|October 3, 2009
TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemiaOlivier Kosmider, Véronique Gelsi-Boyer, Marion Ciudad, et al.
Stem Cells (Dayton, Ohio)|April 12, 2014
TET2 deficiency inhibits mesoderm and hematopoietic differentiation in human embryonic stem cellsThierry Langlois, Barbara da Costa Reis Monte-Mor, Gaëlle Lenglet, et al.
Plos One|September 26, 2013
Heterozygous and homozygous JAK2(V617F) states modeled by induced pluripotent stem cells from myeloproliferative neoplasm patientsJoseph Saliba, Sofiane Hamidi, Gaëlle Lenglet, et al.
Leukemia|September 12, 2024
Eltrombopag in chronic myelomonocytic leukemia with severe thrombocytopenia. A Groupe Francophone des Myélodysplasies (GFM) studyFlorence Rabian, Sylvie Chevret, Bérengère Gruson, et al.
Pageof 28